The three major treatments for cancer are surgery, chemotherapy and radiotherapy, but none of them can prevent the recurrence and metastasis of cancer. Japanese scientists have been studying and clinically using various new methods to prevent cancer recurrence, and cooperating with surgery, radiotherapy and chemotherapy to improve the five-year survival rate of cancer patients. The most important technologies include gene therapy, immunotherapy, vaccine therapy and electric field therapy.
Immune cell therapy in Japan: Japan is in the leading position in the field of immune cell therapy, and the health department of the Japanese government is gradually liberalizing the supervision of immune cell therapy, and a large number of successful cases have appeared in clinic. In Japan, to carry out immunotherapy for cancer, it is necessary to apply through the National Committee of Regenerative Medicine and the local health bureau, and only after strict inspection can the qualification for immunotherapy be obtained. At present, macrophage immunotherapy has been patented and achieved amazing results in clinical trials. The purpose of "immunotherapy" is to find ways to awaken the body's own immune function and attack cancer cells. Experiments show that the combination of immunotherapy and routine therapy has the best effect.
Japanese tumor vaccine therapy: cancer antigens (such as lung cancer antigens/intestinal cancer antigens) extracted from tumor tissues in advance or from autologous body fluids are matched with cultured dendritic cells and adjuvants, and cancer vaccines are tailored according to the types of cancer patients suffer from. Different from health food (Ganoderma lucidum spore powder, Cordyceps sinensis, etc. ), vaccines generally do not improve the body's immunity, but aim to arouse the immune response in cancer patients and actively destroy tumor cells. Up to now, more than 6.5438+0.3 million patients in Japan have been vaccinated against cancer recurrence (including 6.5438+0.6 million patients in Japan and 6,000 patients overseas), and tumor vaccine technology has been patented in the United States, Japan, Singapore and other countries.
Japanese cancer gene therapy: The research of cancer gene therapy has a history of more than ten years. At present, Japan has successfully developed two new gene therapies, namely JG- 1 and E 10A. JG- 1 is a powerful therapy combining CDC6shRNA active gene and "tumor suppressor gene p 16". E 10A is a kind of gene drug that uses virus vector (adenovirus No.5) to introduce endostatin gene, interferon gene and other therapeutic genes into cancer cells and make them have therapeutic effects. Studies have confirmed the safety and effectiveness of cancer gene therapy, and the United States, Japan and other countries with the most advanced medical level have carried out cancer gene therapy.